TY - JOUR T1 - Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy JO - Revista de Gastroenterología de México T2 - AU - Coronel-Castillo,C.E. AU - Contreras-Carmona,J. AU - Frati-Munari,A.C. AU - Uribe,M. AU - Méndez-Sánchez,N. SN - 2255534X M3 - 10.1016/j.rgmxen.2019.09.003 DO - 10.1016/j.rgmxen.2019.09.003 UR - http://revistagastroenterologiamexico.org/en-efficacy-rifaximin-in-different-clinical-articulo-S2255534X19301215 AB - Hepatic encephalopathy (EH) is a common complication among patients with liver cirrhosis associated with a high mortality rate. The costs attributed to the management of patients with cirrhosis are especially high due to complications such as EH, since it increases the days of hospitalization. Currently for the treatment of EH, there are different drugs of which the standout lactulose, L-ornithine, L-aspartate (LOLA) and certain antibiotics, especially rifaximin-α (RFX). Although many of them have been shown to be as effective as the others, in order to that it is important to have information that allows us to discern about each other. Furthermore, that can help to individualize the patient's treatment and choose the best options in different scenarios. Therefore, the objective of this study was to analyze the evidence on the advantages and disadvantages of individual use or in combination of the 3 main treatments of EH, specifically its effectiveness in different grades of EH, its impact on quality of life, prophylaxis and costs reduction. ER -